| Serial Number | 97768059 |
| Word Mark | RAP PLATFORM |
| Filing Date | Wednesday, January 25, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, May 7, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 12, 2024 |
| NOT AVAILABLE | "'PLATFORM'" |
| Goods and Services | Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, autoimmune diseases and disorders, cardiovascular diseases and disorders, connective tissues diseases and disorders, dermatological diseases and disorders, enzyme deficiency diseases and disorders, gastrointestinal diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hematological diseases and disorders, immunoregulatory diseases and disorders, infectious diseases and disorders, inflammatory diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, muscular diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, oncological diseases and disorders, ophthalmological diseases and disorders, rare diseases and disorders, renal diseases and disorders, reproductive disease and disorders, and respiratory diseases and disorders; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and drug discovery services; pharmaceutical research and analysis services using machine learning analytics relating to pharmaceutical drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 30, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CAMP4 Therapeutics Corporation |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02139 |
| Party Name | CAMP4 Therapeutics Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02139 |
| Event Date | Event Description |
| Saturday, January 28, 2023 | NEW APPLICATION ENTERED |
| Monday, January 30, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, February 2, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, May 4, 2023 | ASSIGNED TO LIE |
| Friday, May 5, 2023 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Monday, October 23, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, November 15, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 15, 2023 | NON-FINAL ACTION E-MAILED |
| Wednesday, November 15, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, February 6, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 6, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 7, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 8, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 21, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, February 21, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 12, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 12, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 7, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, November 7, 2024 | TEAS STATEMENT OF USE RECEIVED |